X-rays could help to make reliable, rapid COVID-19 tests latinamericanpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from latinamericanpost.com Daily Mail and Mail on Sunday newspapers.
Luján Introduces Legislation To Bolster Research And Development To Tackle COVID-19 And Emerging Biothreats
U.S. SENATE News:
WASHINGTON, D.C. U.S. Sen. Ben Ray Luján (D-N.M.) introduced the National Laboratory Biotechnology Research Act to create a National Laboratory Biotechnology Program within the Department of Energy (DOE) to fund research and development related to the COVID-19 pandemic and long-term biothreats.
The Program is modeled after the National Virtual Biotechnology Laboratory (NVBL) that was created using funds from the Coronavirus Aid, Relief, and Economic Security (CARES) Act that passed in March 2020. The NVBL is a model for the future and its research can be used to strengthen our national response to emerging biotechnology threats facing the United States.
Loading video.
VIDEO: Scientists at Sandia National Laboratories are using high-performance computers to simulate how liquid droplets expelled by coughs react to different environments, including a plexiglass barrier. view more
Credit: Video by Sandia National Laboratories
ALBUQUERQUE, N.M. Two groups of researchers at Sandia National Laboratories have published papers on the droplets of liquid sprayed by coughs or sneezes and how far they can travel under different conditions.
Both teams used Sandia s decades of experience with advanced computer simulations studying how liquids and gases move for its nuclear stockpile stewardship mission.
Their findings reinforce the importance of wearing masks, maintaining social distancing, avoiding poorly ventilated indoor spaces and washing your hands frequently, especially with the emergence of new, more transmissible variants of SARS-CoV-2, the virus that causes COVID-19.
Argonne s Advanced Photon Source guided the development of new COVID-19 vaccine now in trials
Human clinical trials have begun on a new vaccine candidate that may protect against not only SARS-CoV-2, the virus that causes COVID-19, but against at least two of the variants emerging around the world. The development of this new vaccine was guided by structural information on the virus obtained at the Advanced Photon Source (APS), a U.S. Department of Energy (DOE) Office of Science User Facility at DOE s Argonne National Laboratory, and other light sources.
Trials are taking place at the Walter Reed Army Institute of Research (WRAIR), part of the U.S. Army Medical Research and Development Command, following up on early tests that showed promising results.
Faster air exchange in buildings not always beneficial for coronavirus levels eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.